When a new definition overhauls perceptions of MAFLD related cirrhosis care.
作者信息
Zheng Kenneth I, Eslam Mohammed, George Jacob, Zheng Ming-Hua
机构信息
MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia.
出版信息
Hepatobiliary Surg Nutr. 2020 Dec;9(6):801-804. doi: 10.21037/hbsn-20-725.
Abstract
摘要
相似文献
1
When a new definition overhauls perceptions of MAFLD related cirrhosis care.当一个新定义彻底改变了对MAFLD相关肝硬化护理的认知时。
Hepatobiliary Surg Nutr. 2020 Dec;9(6):801-804. doi: 10.21037/hbsn-20-725.
2
Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China.中国新乡地区代谢相关脂肪性肝病的流行状况及其危险因素分析。
Int J Environ Res Public Health. 2020 Mar 11;17(6):1818. doi: 10.3390/ijerph17061818.
3
Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models.使用肥胖小鼠模型评估代谢功能障碍相关脂肪性肝病中的线粒体功能。
Zool Res. 2020 Sep 18;41(5):539-551. doi: 10.24272/j.issn.2095-8137.2020.051.
4
Tandem Mass Tag-based quantitative proteomics analysis of metabolic associated fatty liver disease induced by high fat diet in mice.基于串联质量标签的高脂饮食诱导小鼠代谢相关脂肪性肝病的定量蛋白质组学分析
Nutr Metab (Lond). 2020 Nov 18;17(1):97. doi: 10.1186/s12986-020-00522-3.
5
MAFLD in COVID-19 patients: an insidious enemy.COVID-19 患者中的 MAFLD：一个隐而难测的敌人。
Expert Rev Gastroenterol Hepatol. 2020 Oct;14(10):867-872. doi: 10.1080/17474124.2020.1801417. Epub 2020 Aug 4.
6
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD.神经降压素上调与 MAFLD 患者的晚期纤维化和肝细胞癌有关。
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Oct;1865(10):158765. doi: 10.1016/j.bbalip.2020.158765. Epub 2020 Jul 11.
7
Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.TLL1 基因的遗传变异与代谢相关脂肪性肝病患者的纤维化无关。
PLoS One. 2020 Dec 11;15(12):e0243590. doi: 10.1371/journal.pone.0243590. eCollection 2020.
8
Reinvention. Health care organizations start overhauls for a new delivery model.重塑。医疗保健机构开始对新的交付模式进行全面改革。
Hosp Health Netw. 2012 May;86(5):54-8.
9
SBME overhauls health care delivery structure.基于模拟的医学教育（SBME）彻底改革了医疗保健提供结构。
N J Med. 1992 Jun;89(6):469-71.
10
Emergency physician– turned-governor overhauls Oregon’s health care.从急诊医生转型为州长的人全面改革了俄勒冈州的医疗保健体系。
Ann Emerg Med. 2011 Jul;58(1):13A-14A. doi: 10.1016/j.annemergmed.2011.04.034.
引用本文的文献
1
Immune infiltration analysis based on pyroptosis-related gene in metabolic dysfunction-associated fatty liver disease.基于焦亡相关基因的代谢功能障碍相关脂肪性肝病免疫浸润分析
Heliyon. 2024 Jul 9;10(15):e34348. doi: 10.1016/j.heliyon.2024.e34348. eCollection 2024 Aug 15.
2
Endohepatology: The endoscopic armamentarium in the hand of the hepatologist.内科学：肝病学家手中的内镜设备。
Saudi J Gastroenterol. 2024 Jan 1;30(1):4-13. doi: 10.4103/sjg.sjg_214_23. Epub 2023 Nov 18.
3
Association of non-alcoholic fatty liver disease with total testosterone in non-overweight/obese men with type 2 diabetes mellitus.非超重/肥胖 2 型糖尿病男性患者非酒精性脂肪性肝病与总睾酮的相关性。
J Endocrinol Invest. 2023 Aug;46(8):1565-1572. doi: 10.1007/s40618-023-02006-6. Epub 2023 Feb 1.
4
rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease.rs738409 C>G变异影响经活检证实的非酒精性脂肪性肝病中内脏脂肪与显著纤维化之间的关联。
J Clin Transl Hepatol. 2022 Jun 28;10(3):439-448. doi: 10.14218/JCTH.2021.00286. Epub 2021 Oct 22.
5
Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease.非肥胖非酒精性脂肪性肝病患者及高危人群的生活方式干预。
Diabetes Metab J. 2022 May;46(3):391-401. doi: 10.4093/dmj.2022.0048. Epub 2022 May 25.
6
Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease.代谢功能障碍相关脂肪性肝病比非酒精性脂肪性肝病与更严重的肺功能损害相关。
J Clin Transl Hepatol. 2022 Apr 28;10(2):230-237. doi: 10.14218/JCTH.2021.00306. Epub 2022 Jan 4.
7
Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.马来西亚胃肠病学和肝脏病学会关于代谢功能障碍相关脂肪性肝病的共识声明。
J Gastroenterol Hepatol. 2022 May;37(5):795-811. doi: 10.1111/jgh.15787. Epub 2022 Feb 8.
8
The uprising of metabolic dysfunction-associated fatty liver disease (MAFLD) in acute-on-chronic liver failure (ACLF).代谢功能障碍相关脂肪性肝病（MAFLD）在慢性肝衰竭急性发作（ACLF）中的发生率上升。
Hepatobiliary Surg Nutr. 2021 Dec;10(6):857-859. doi: 10.21037/hbsn-21-431.
9
Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future.代谢（功能障碍）相关脂肪性肝病：更多证据与光明前景
Hepatobiliary Surg Nutr. 2021 Dec;10(6):849-852. doi: 10.21037/hbsn-21-352.
10
Metabolic-associated Fatty Liver Disease.代谢相关脂肪性肝病
J Clin Transl Hepatol. 2021 Dec 28;9(6):793-794. doi: 10.14218/JCTH.2021.00439. Epub 2021 Nov 9.
本文引用的文献
1
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.亚太肝病学会代谢相关性脂肪性肝病临床诊疗指南。
Hepatol Int. 2020 Dec;14(6):889-919. doi: 10.1007/s12072-020-10094-2. Epub 2020 Oct 1.
2
Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.验证巴韦诺VI标准及扩展的巴韦诺VI标准以识别与MAFLD相关的代偿期肝硬化患者中的高危静脉曲张。
J Hepatol. 2020 Dec;73(6):1571-1573. doi: 10.1016/j.jhep.2020.06.042. Epub 2020 Sep 21.
3
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.代谢相关脂肪性肝病新定义：国际专家共识声明。
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
4
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.MAFLD：代谢相关脂肪性肝病的共识驱动命名建议。
Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.
5
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.一项关于欧洲对非酒精性脂肪性肝病公共卫生应对措施的横断面研究。
J Hepatol. 2020 Jan;72(1):14-24. doi: 10.1016/j.jhep.2019.08.027. Epub 2019 Sep 10.
6
Is cryptogenic cirrhosis different from NASH cirrhosis?隐匿性肝硬化与非酒精性脂肪性肝炎相关性肝硬化是否不同？
J Hepatol. 2018 Mar;68(3):519-525. doi: 10.1016/j.jhep.2017.11.018. Epub 2017 Nov 21.
7
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.对非酒精性脂肪性肝病流行情况的建模显示，疾病负担呈指数级增长。
Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1.
8
Implementation of a 'care bundle' improves the management of patients admitted to hospital with decompensated cirrhosis.实施“护理包”可改善失代偿期肝硬化住院患者的管理。
Aliment Pharmacol Ther. 2016 Nov;44(10):1030-1038. doi: 10.1111/apt.13806. Epub 2016 Sep 26.
9
Treatment of Patients with Cirrhosis.肝硬化患者的治疗
N Engl J Med. 2016 Aug 25;375(8):767-77. doi: 10.1056/NEJMra1504367.
10
Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.门静脉高压领域共识的拓展：巴韦诺VI共识研讨会报告：门静脉高压风险分层与个体化治疗
J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.
Zotero 插件